Inflammatory cytokines in human pancreatic cancer

Cancer Letters

Volumn 345, Issue 2, 2014, Pages 157-163

  Roshani, Rozita ^a   McCarthy, Fiona ^a   Hagemann, Thorsten ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cytokine; Immune evasion; Inflammation; Pancreatic cancer

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MACROPHAGE MIGRATION INHIBITION FACTOR MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PLACEBO; THALIDOMIDE; TRABEDERSEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CACHEXIA; CANCER GROWTH; CANCER RADIOTHERAPY; CARCINOGENESIS; CYTOKINE PRODUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATION; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS SURGERY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SOLID TUMOR; TUMOR MICROENVIRONMENT; VIRAL GENE THERAPY;

CYTOKINE; IMMUNE EVASION; INFLAMMATION; PANCREATIC CANCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84896690616     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.014     Document Type: Review

References (92)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46:765-781.
3. Seufferlein T., Bachet J.B., Van Cutsem E., Rougier P. Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012, 23(Suppl 7):vii33-vii40.
4. Loos M., Kleeff J., Friess H., Buchler M.W. Surgical treatment of pancreatic cancer. Ann. N. Y. Acad. Sci. 2008, 1138:169-180.
5. Xie K., Li D., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363:1049-1057.
6. Sultana A., Smith C.T., Cunningham D., Starling N., Neoptolemos J.P., Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2007, 25:2607-2615.
7. F. Desseigne, T. Conroy, M. Ychou, M. Ducreux, O. Bouche, R. Guimbaud, Y. Becouarn, C. Montoto-Grillot, S. Gourgou-Bourgade, A, Adenis. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial, J. Clin. Oncol. 28 (2010).
8. Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Reichert M., Beatty G.L., Rustgi A.K., Vonderheide R.H., Leach S.D., Stanger B.Z. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361.
9. Guerra C., Schuhmacher A.J., Canamero M., Grippo P.J., Verdaguer L., Perez-Gallego L., Dubus P., Sandgren E.P., Barbacid M. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007, 11:291-302.
10. Malka D., Hammel P., Maire F., Rufat P., Madeira I., Pessione F., Levy P., Ruszniewski P. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002, 51:849-852.
11. Sugiyama Y., Farrow B., Chen A., Uffort E., Nealon W., Evers B.M. Inflammatory mechanisms contributing to pancreatic cancer development. Ann. Surg. 2004, 239:763-771.
12. Navas C., Hernandez-Porras I., Schuhmacher A.J., Sibilia M., Guerra C., Barbacid M. EGF receptor signaling is essential for K-Ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012, 22:318-330.
13. Ardito C.M., Gruner B.M., Takeuchi K.K., Lubeseder-Martellato C., Teichmann N., Mazur P.K., Delgiorno K.E., Carpenter E.S., Halbrook C.J., Hall J.C., Pal D., Briel T., Herner A., Trajkovic-Arsic M., Sipos B., Liou G.Y., Storz P., Murray N.R., Threadgill D.W., Sibilia M., Washington M.K., Wilson C.L., Schmid R.M., Raines E.W., Crawford H.C., Siveke J.T. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012, 22:304-317.
14. Fujiwara Y., Shiba H., Iwase R., Haruki K., Furukawa K., Uwagawa T., Misawa T., Ohashi T., Yanaga K. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice. J. Am. Coll. Surg. 2013, 216:320-332. e323.
15. Miraglia S., Uomo I., Pastorello M. Inflammation and pancreatic ductal adenocarcinoma: a potential scenario for novel drug targets. JOP. J. Pancreas 2010, 11:199-202.
16. Feig C., Gopinathan A., Neesse A., Chan D.S., Cook N., Tuveson D.A. The pancreas cancer microenvironment. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2012, 18:4266-4276.
17. Gavazzi F., Tassi E., Albarello L., Senyukov V., Longhi R., Dellabona P., Doglioni C., Braga M., Di Carlo V., Protti M.P. Carcinoembryonic antigen-specific but not antiviral CD4+T cell immunity is impaired in pancreatic carcinoma patients. J. Immunol. 2008, 181:6595-6603.
18. Kim E.J., Simeone D.M. Advances in pancreatic cancer. Curr. Opin. Gastroenterol. 2011, 27:460-466.
19. Verma G., Bhatia H., Datta M. Gene expression profiling and pathway analysis identify the integrin signaling pathway to be altered by IL-1b in human pancreatic cancer cells: role of JNK. Cancer Lett. 2012, 320:86-95.
20. O'Shea J.J., Holland S.M., Staudt L.M. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med. 2013, 368:161-170.
21. Feurino L.W., Fisher W.E., Bharadwaj U., Yao Q., Chen C., Li M. Current update of cytokines in pancreatic cancer: pathogenic mechanisms, clinical indication, and therapeutic values. Cancer Invest. 2006, 24:696-703.
22. Ling J., Kang Y., Zhao R., Xia Q., Lee D.F., Chang Z., Li J., Peng B., Fleming J.B., Wang H., Liu J., Lemischka I.R., Hung M.C., Chiao P.J. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:105-120.
23. Carbone A., Bellone G., Smirne C., Scirelli T., Buffolino A., Novarino A., Stacchini A., Bertetto O., Palestro G., Sorio C., Scarpa A., Emanuelli Giorgio, Rodeck ulrich cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J. Immunol. 2006, 177:3448-3460.
24. Hu C., Funamizu N., Lacy C., Schetter A., Zhang G., He P., Gaedcke J., Ghadimi M.B., Ried T., Yfantis H.G., Lee D.H., Subleski J., Chan T., Weiss J.M., Back T.C., Yanaga K., Hanna N., Alexander H.R., Maitra A., Hussain S.P. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int. J. Cancer 2012, 132:785-794.
25. Kurkowski M.U., Lesina M., Ludes K., Rose-John S., Treiber M., Kloppel G., Yoshimura A., Reindl W., Sipos B., Akira S., Schmid R.M., Algu H. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
26. Kunze P., Martignoni M.E., Hildebrandt W., Kunzli B., Berberat P., Giese T., Kloters O., Hammer J., Buchler M.W., Giese N.A., Friess H. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin. Cancer Res. 2005, 11:5802-5808.
27. Tucker S.L., Ebrahimi B., Li D., Abbruzzese J.L., Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 2004, 101:2727-2736.
28. Zhang Y., Li M., Feurino L.W., Wang H., Fisher W.E., Brunicardi F.C., Chen C., Yao Q. Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer. Cancer Sci. 2008, 99:733-737.
29. Miron N., Miron M.M., Milea V.G., Cristea V. Proinflammatory cytokines: an insight into pancreatic oncogenesis. Roum. Arch. Microbiol. Immunol. 2010, 69:183-189.
30. Smirne C., Bellone G., Mauri F.A., Tonel E., Carbone A., Buffolino A., Dughera L., Robecchi A., Pirisi M., Emanuelli G. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol. Immunother. 2006, 55:684-698.
31. Dima S.O., Tanase C., Albulescu R., Herlea V., Chivu-Economescu M., Purnichescu-Purtan R., Dumitrascu T., Duda D.G., Popescu I. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas 2012, 41:1001-1007.
32. Poch B., Lotspeich E., Ramadani M., Gansauge S., Beger H.G., Gansauge F. Systemic immune dysfunction in pancreatic cancer patients. Langenbecks Arch Surg. 2007, 392:353-358.
33. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., Ng C.S., Badmaev V., Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2008, 14:4491-4499.
34. Winner M., Koong A.C., Rendon B.E., Zundel W., Mitchell R.A. Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res. 2007, 67:186-193.
35. Fearon K.C., Glass D.J., Guttridge D.C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012, 16:153-166.
36. M. Tsoli, G. Robertson, Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem, Trends Endocrinol Metab (2012).
37. Tisdale M.J. Cancer cachexia. Curr. Opin. Gastroenterol. 2010, 26:146-151.
38. M. Ikeda, S. Mitsunaga, K. Nakachi, E. Suzuki, J. Furuse, M. Inagaki, Y. Uchitomi, S. Higashi, K. Terao, A. Ochiai, Role of IL-6 in cachexia progression in advanced pancreatic cancer, J. Clin. Oncol., 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 28 (2010).
39. Talar-Wojnarowska R., Gasiorowska A., Smolarz B., Romanowicz-Makowska H., Kulig A., Malecka-Panas E. Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma 2009, 56:56-62.
40. Gordon J.N., Trebble T.M., Ellis R.D., Duncan H.D., Johns T., Goggin P.M. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005, 54:540-545.
41. Wiedenmann B., Malfertheiner P., Friess H., Ritch P., Arseneau J., Mantovani G., Caprioni F., Van Cutsem E., Richel D., DeWitte M., Qi M., Robinson D., Zhong B., De Boer C., Lu J.D., Prabhakar U., Corringham R., Von Hoff D. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J. Support Oncol. 2008, 6:18-25.
42. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 2012, 33:571-577.
43. Wang W., Yu Y., Zhai S., Dang S., Sun M. IL6 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review. Mol. Biol. Rep. 2012, 39:8457-8463.
44. Wang S.X., Tang R.F., Zhang F.R., Peng L., Wang S.X., Xiao Y., Zhang M. Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer. Hepatobilliary Pancreat Dis. Int. 2005, 4:460-463.
45. Falconer J.S., Fearon K.C., Plester C.E., Ross J.A., Carter D.C. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann. Surg. 1994, 219:325-331.
46. Okada S., Okusaka T., Ishii H., Kyogoku A., Yoshimori M., Kajimura N., Yamaguchi K., Kakizoe T. Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn. J. Clin. Oncol. 1998, 28:12-15.
47. Clark-Lewis I., Baggiolini M. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992, 307:97-101.
48. Konno H., Ohta M., Baba M., Suzuki S., Nakamura S. The role of circulating IL-8 and VEGF protein in the progression of gastric cancer. Cancer Sci. 2003, 94:735-740.
49. Lurje G., Zhang W., Schultheis A.M., Yang D., Groshen S., Hendifar A.E., Husain H., Gordon M.A., Nagashima F., Chang H.M., Lenz H.J. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann. Oncol. 2008, 19:1734-1741.
50. Derin D., Soydinc H.O., Guney N., Tas F., Camlica H., Duranyildiz D., Yasasever V., Topuz E. Serum IL-8 and IL-12 levels in breast cancer. Med. Oncol. 2007, 24:163-168.
51. A.A., W. Li, M. Li, Inflammation and pancreatic cancer: a tale of two cytokines, Cell. Biol.: Res. Ther. 1 (2012).
52. O.N., Y. Matsuo, H. Sawai, A. Yasuda, H. Takahashi, H. Funahashi, H. Takeyama, Z. Tong, S. Guha, CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer, Int. J. Cancer 124 (2009) 853-561.
53. S.T., Y. Kuwada, K. Morinaka, Y. Kitadai, N. Mukaida, K. Chayama, Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells, Int. J. Oncol. 22 (2003) 765-771.
54. Wigmore S.J., Fearon K.C., Sangster K., Maingay J.P., Garden O.J., Ross J.A. Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int. J. Oncol. 2002, 21:881-886.
55. S.M., Y. Chen, G.Z. Yu, X.R. Qin, G. Jin, P. Chen, M.H. Zhu, Interleukin-8, a promising predictor for prognosis of pancreatic cancer, World J. Gastroenterol. 18 (2012) 1123-1129.
56. Chu W.M. Tumor necrosis factor. Cancer Lett. 2013, 328:222-225.
57. Balkwill F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 2009, 9:361-371.
58. Friess H., Guo X.Z., Nan B.C., Kleeff J., Buchler M.W. Growth factors and cytokines in pancreatic carcinogenesis. Ann. N. Y. Acad. Sci. 1999, 880:110-121.
59. Egberts J.H., Cloosters V., Noack A., Schniewind B., Thon L., Klose S., Kettler B., von Forstner C., Kneitz C., Tepel J., Adam D., Wajant H., Kalthoff H., Trauzold A. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008, 68:1443-1450.
60. Robinson D.W., Eisenberg D.F., Cella D., Zhao N., de Boer C., DeWitte M. The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J. Support Oncol. 2008, 6:283-290.
61. C. Wu, S.A. Fernandez, T. Criswell, T.A. Chidiac, D. Guttridge, M. Villalona-Calero, T.S. Bekaii-Saab, Disrupting cytokine signaling in pancreatic cancer: a Phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease, Pancreas (2013).
62. Hecht J.R., Farrell J.J., Senzer N., Nemunaitis J., Rosemurgy A., Chung T., Hanna N., Chang K.J., Javle M., Posner M., Waxman I., Reid A., Erickson R., Canto M., Chak A., Blatner G., Kovacevic M., Thornton M. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest. Endosc. 2012, 75:332-338.
63. Bloom B.R., Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966, 153:80-82.
64. Calandra T., Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 2003, 3:791-800.
65. N.J, T. Ohkawara, H. Takeda, M. Asaka, T. Sugiyama, Pathophysiological roles of macrophage migration inhibitory factor in gastrointestinal, hepatic, and pancreatic disorders. J. Gastroenterol. 40 (2005).
66. H.T., J. Candido, Cancer-related inflammation, J. Clin. Immunol. 33 (2013) S79-S84.
67. Denz A., Pilarsky C., Muth D., Ruckert F., Saeger H.D., Grutzmann R. Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. J. Surg. Res. 2010, 160:29-34.
68. Bach J.P., Deuster O., Balzer-Geldsetzer M., Meyer B., Dodel R., Bacher M. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 2009, 115:2031-2040.
69. R.s., T. Hagemann, R. Thompson, K.A. Charles, H. Kulbe, F.R. Balkwill, Ovarian cancer cell-derived MIF enhances tumour growth, progression and angiogenesis, Mol. Cancer Ther. 6 (2007) 1-10.
70. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
71. Apte R.N., Dotan S., Elkabets M., White M.R., Reich E., Carmi Y., Song X., Dvozkin T., Krelin Y., Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metast. Rev. 2006, 25:387-408.
72. Greco E., Basso D., Fogar P., Mazza S., Navaglia F., Zambon C.F., Falda A., Pedrazzoli S., Ancona E., Plebani M. Pancreatic cancer cells invasiveness is mainly affected by interleukin-1beta not by transforming growth factor-beta1. Int. J. Biol. Markers 2005, 20:235-241.
73. Arlt A., Vorndamm J., Muerkoster S., Yu H., Schmidt W.E., Folsch U.R., Schafer H. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res. 2002, 62:910-916.
74. Angst E., Reber H.A., Hines O.J., Eibl G. Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery 2008, 144:57-65.
75. Schmid M.C., Avraamides C.J., Foubert P., Shaked Y., Kang S.W., Kerbel R.S., Varner J.A. Combined blockade of integrin-alpha4beta1 plus cytokines SDF-1alpha or IL-1beta potently inhibits tumor inflammation and growth. Cancer Res. 2011, 71:6965-6975.
76. Dinarello C. Why not treat human cancer with interleukin-1 blockade?. Cancer Metastasis Rev. 2010, 29:317-329.
77. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
78. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29:235-271.
79. Roussos E.T., Condeelis J.S., Patsialou A. Chemotaxis in cancer. Nat. Rev. Cancer 2011, 11:573-587.
80. Lin Y., Kikuchi S., Tamakoshi A., Obata Y., Yagyu K., Inaba Y., Kurosawa M., Kawamura T., Motohashi Y., Ishibashi T. Serum transforming growth factor-beta1 levels and pancreatic cancer risk: a nested case-control study (Japan). Cancer Causes Control 2006, 17:1077-1082.
81. U.R., M.J. Truty, Transforming growth factor-beta: what every pancreatic surgeon should know, Surgery 141 (2007) 1-6.
82. B.B., C. Alvarez, Role of transforming growth factor-beta in growth and injury response of the pancreatic duct epithe- lium in vitro, J. Gastrointest Surg. 3 (1999) 178-184.
83. Birnbaum D.J., Mamessier E., Birnbaum D. The emerging role of the TGFbeta tumor suppressor pathway in pancreatic cancer. Cell Cycle 2012, 11:683-686.
84. T.A., G. Bellone, E. Artusio, K. Mareschi, A. Carbone, D. Tibaudi, A. Robecchi, G. Emanuelli, U. Rodeck, Tumor-associated transforming growth factor- β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients, Am. J. Pathol. 155 (1999) 537-547.
85. Ouyang W., Rutz S., Crellin N.K., Valdez P.A., Hymowitz S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 2011, 29:71-109.
86. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
87. Fietta P., Delsante G. The effector T helper cell triade. Riv. Biol. 2009, 102:61-74.
88. Nakayamada S., Takahashi H., Kanno Y., O'Shea J.J. Helper T cell diversity and plasticity. Curr. Opin. Immunol. 2012, 24:297-302.
89. De Monte L., Reni M., Tassi E., Clavenna D., Papa I., Recalde H., Braga M., Di Carlo V., Doglioni C., Protti M.P. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 2011, 208:469-478.
90. von Bernstorff V.W., Freichel S., Schmid A., Vogel I., Johnk C., Henne-Bruns D., Kremer B., Kalthoff H. Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res. 2001, 7:925s-932s.
91. S.T., H. Oettle, T. Luger, R.M. Schmid, G. von Wichert, E. Endlicher, C. Garbe, K.K. Kaehler, A. Enk, A. Schneider, T. Rothhammer-Hampl, S. Grosser, et al., Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with Trabedersen, J. Clin. Oncol. 30(Suppl):Abstract 4034 (2012).
92. Luo Y. Blocking IL-10 enhances bacillus Calmette-Guerin induced T helper Type 1 immune responses and anti-bladder cancer immunity. Oncoimmunology 2012, 1:1183-1185.